Navigation Links
Savient Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
Date:8/6/2012

EAST BRUNSWICK, N.J., Aug. 6, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Lou Ferrari, President and Chief Executive Officer, will present at the Canaccord Genuity 32nd Annual Growth Conference on Thursday, August 16, 2012 at 1:00 PM Eastern Time.  The conference will be held at the InterContinental Hotel in Boston, MA.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT – GContact:Mary ColemanCarney Noensie
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals Adopts Stockholder Rights Plan
2. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
3. Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
4. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
5. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
6. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
7. TWi Pharmaceuticals Announces Positive Phase IIb Clinical Trial Results of AC-201 in Patients with Type 2 Diabetes.
8. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
9. Cumberland Pharmaceuticals Reports Second Quarter 2012 Financial Results
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
11. Global Pharmaceuticals Market 2011-2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical ... proprietary products to treat voiding dysfunctions, today reported ... ended June 30, 2014.  Global revenue for ... 19% to $4.1 million, as compared to $3.4 ... year.  Total revenue for the fiscal first quarter ...
(Date:7/24/2014)... July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... 2014.  Provided below are the highlights: , ... quarter compared with the prior year. Reported sales increased ... , Net earnings per diluted share as reported (EPS) ... of 2013. Adjusted EPS was $2.57, an increase of ...
(Date:7/24/2014)... 24, 2014 Amgen (NASDAQ: AMGN ) ... results on Tuesday, July 29, 2014, after the close of ... a conference call with the investment community at 2 p.m. ... Robert A. Bradway , chairman and chief executive officer, and ... audio of the conference call will be simultaneously broadcast over ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... March 12 Genta,Incorporated (Nasdaq: GNTA ) today announced ... 31, 2007. The Company noted,significant recent milestones, including:, ... biomarker initiates in melanoma -- New oral product, ... 505(b)(2) strategy -- Tesetaxel, a leading ...
... Achieve Weight Loss with Education & ... ... Findings in the Journal of,the American Medical Association on the largest ... prevention.,The combination of both personal contact and web-based support are,identified as ...
Cached Medicine Technology:Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 2Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 3Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 4Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 5Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 6Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 7Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 8Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 9Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 10Study Finds Personal and Web-Based Support Equal Weight Loss Success 2Study Finds Personal and Web-Based Support Equal Weight Loss Success 3Study Finds Personal and Web-Based Support Equal Weight Loss Success 4
(Date:7/25/2014)... be treated more quickly after Manchester research , ... blood test on arrival, is effective in reducing ... study shows., The findings of a research group ... could potentially make a huge difference to a ... most common reason for emergency hospital admission. In ...
(Date:7/25/2014)... some patients is real and is only natural. However, ... in Cancer , the incidence and effects of ... computed tomography (CT) lung cancer screening exams are far ... , "Unsubstantiated claims of systemic and harmful patient ... continue to delay implementation of CT lung cancer screening ...
(Date:7/25/2014)... Ross A. Clevens, MD, FACS, and ... join the exclusive Obagi Clinical Advisory Board, comprised of ... plastic surgeons and dermatologists. , Dr. Clevens recently ... of thought leaders held its first meeting in three ... give Obagi the opportunity to meet with eight of ...
(Date:7/25/2014)... A report released by the Juvenile Diabetes ... 2013 (July 1, 2012- June 30, 2013). , Outside of ... is the largest single funder of type 1 diabetes research ... with most of the top research centers. There is ... 1 diabetes in the near future. , Since the 2008 ...
(Date:7/25/2014)... HealthDay Reporter , THURSDAY, July ... girls and boys are getting the human papillomavirus (HPV) vaccine, ... officials said Thursday. The U.S. Centers for Disease Control ... 12 get the three-dose vaccine so that protection is in ... Yet, despite a slight increase over the year before, only ...
Breaking Medicine News(10 mins):Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:ACR statement on cancer study regarding patient anxiety from CT lung cancer screening 2Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2Health News:Too Few Teens Receive HPV Shot, CDC Says 2Health News:Too Few Teens Receive HPV Shot, CDC Says 3
... George Dahlman, senior vice president of public policy for ... the U.S. Senate Subcommittee on Defense Appropriations, calling for ... at the Department of Defense (DoD). , , ... blood cancers, including chronic lymphocytic leukemia (CLL), lymphoma and ...
... ... DIA Meeting in San Diego, Calif. , ... Boston, Mass. (PRWEB) June 18, 2009 -- CenterWatch , ... annual surveys aimed at better understanding physician referrals to clinical trials and study volunteer ...
... healthcare alliance Innovation Celebration , , ANAHEIM, Calif., June ... medical devices SpA, Italy, yesterday introduced a new innovation in ... fit in the palm of a hand, can record a ... the thumbs. , , The ecg@home(TM) debuted at ...
... June 18 Vendormate, the market leader in vendor ... the role of president, effective immediately. Andy Monin, ... and developing strategic opportunities. , ... success of Vendormate, steadily guiding our processes, systems, and ...
... effect on relationships and lead to significant changes in how ... and emotional level, according a study in the June issue ... from Northern Ireland have come up with four key recommendations ... nine males and seven females, aged between 33 and 78. ...
... - 2009 rankings include 10 specialties and Honor Roll - ... Group today released its second annual rankings by specialty of ... and featured in the August issue of ... July 21. , , The 2009 America,s Best ...
Cached Medicine News:Health News:The Leukemia & Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 2Health News:CenterWatch to Introduce Key Findings from Surveys on Physician Referrals to Clinical Trials and Clinical Trial Volunteer Experiences at DIA Meeting 2Health News:HealthFrontier Introduces New Innovation in Web-Based Remote Health Monitoring Technology 2Health News:Bill Hayes Promoted to President of Vendormate 2Health News:Stroke survivors report loss of sexual desire, blurred gender roles, anger and fatigue 2Health News:Stroke survivors report loss of sexual desire, blurred gender roles, anger and fatigue 3Health News:Stroke survivors report loss of sexual desire, blurred gender roles, anger and fatigue 4Health News:U.S. News Media Group Releases Rankings of America's Best Children's Hospitals 2Health News:U.S. News Media Group Releases Rankings of America's Best Children's Hospitals 3
... ophthalmic solution is an anti-infective ... doctor may instruct you to ... eye infection caused by bacteria. ... are the 2 types of ...
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% is medication in the form of an eye drop that is used to lower the pressure inside your eye(s), also referred to as intraocular pressu...
ALOCRIL® ophthalmic solution is a prescription eye drop for itchy allergy eyes. ALOCRIL® provides control beyond relief by providing continuous symptom control throughout the allergy season....
Medicine Products: